GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BELLUS Health Inc (TSX:BLU) » Definitions » EV-to-EBIT

BELLUS Health (TSX:BLU) EV-to-EBIT : -17.75 (As of Apr. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is BELLUS Health EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BELLUS Health's Enterprise Value is C$2,057.09 Mil. BELLUS Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was C$-115.89 Mil. Therefore, BELLUS Health's EV-to-EBIT for today is -17.75.

The historical rank and industry rank for BELLUS Health's EV-to-EBIT or its related term are showing as below:

TSX:BLU' s EV-to-EBIT Range Over the Past 10 Years
Min: -318.26   Med: -24.05   Max: 225.58
Current: -17.97

During the past 13 years, the highest EV-to-EBIT of BELLUS Health was 225.58. The lowest was -318.26. And the median was -24.05.

TSX:BLU's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.05 vs TSX:BLU: -17.97

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BELLUS Health's Enterprise Value for the quarter that ended in Mar. 2023 was C$803.48 Mil. BELLUS Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was C$-115.89 Mil. BELLUS Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -14.42%.


BELLUS Health EV-to-EBIT Historical Data

The historical data trend for BELLUS Health's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BELLUS Health EV-to-EBIT Chart

BELLUS Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.63 -12.74 -4.48 -8.53 -9.28

BELLUS Health Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.17 -10.83 -13.27 -9.28 -6.93

Competitive Comparison of BELLUS Health's EV-to-EBIT

For the Biotechnology subindustry, BELLUS Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BELLUS Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BELLUS Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BELLUS Health's EV-to-EBIT falls into.



BELLUS Health EV-to-EBIT Calculation

BELLUS Health's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2057.088/-115.889
=-17.75

BELLUS Health's current Enterprise Value is C$2,057.09 Mil.
BELLUS Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-115.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BELLUS Health  (TSX:BLU) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BELLUS Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 ) =EBIT / Enterprise Value (Q: Mar. 2023 )
=-115.889/803.47964
=-14.42 %

BELLUS Health's Enterprise Value for the quarter that ended in Mar. 2023 was C$803.48 Mil.
BELLUS Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-115.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BELLUS Health EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BELLUS Health's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BELLUS Health (TSX:BLU) Business Description

Traded in Other Exchanges
N/A
Address
275 Armand-Frappier Boulevard, Laval, QC, CAN, H7V 4A7
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

BELLUS Health (TSX:BLU) Headlines